Libtayo® Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
Pasatru Demonstrates Zero New Heterotopic Ossification Lesions in Adult Fibrodysplasia Ossificans Progressiva Patients During OPTIMA Trial Extension
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Ubamatamab Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
Pasatru First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak
Lynozyfic® Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
Brixton Metals Announces Closing of Option Agreement to Acquire a 100% Interest in the Silver Focused Silvergruvan Project in Sweden
Spartan Metals Expands Victorio Tungsten-Molybdenum Resource with Measured and Indicated Grades of 0.25% MoEq or 0.15% WO3Eq
